U.S. Markets closed
  • S&P 500

    4,419.02
    +18.38 (+0.42%)
     
  • Dow 30

    35,084.14
    +153.21 (+0.44%)
     
  • Nasdaq

    14,778.26
    +15.68 (+0.11%)
     
  • Russell 2000

    2,243.99
    +19.03 (+0.86%)
     
  • Crude Oil

    73.60
    +1.21 (+1.67%)
     
  • Gold

    1,832.90
    +28.30 (+1.57%)
     
  • Silver

    25.61
    +0.74 (+2.97%)
     
  • EUR/USD

    1.1891
    +0.0044 (+0.3686%)
     
  • 10-Yr Bond

    1.2690
    +0.0080 (+0.63%)
     
  • Vix

    17.40
    -0.91 (-4.97%)
     
  • GBP/USD

    1.3966
    +0.0057 (+0.4078%)
     
  • USD/JPY

    109.4580
    -0.4520 (-0.4112%)
     
  • BTC-USD

    39,709.68
    -656.66 (-1.63%)
     
  • CMC Crypto 200

    934.45
    +4.09 (+0.44%)
     
  • FTSE 100

    7,078.42
    +61.79 (+0.88%)
     
  • Nikkei 225

    27,782.42
    +200.76 (+0.73%)
     

G1 Therapeutics to Present at Stifel Healthcare Conference on November 19, 2019

RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present a company overview at the Stifel Healthcare Conference. The presentation will take place on Tuesday, November 19, 2019 at 9:45 a.m. at the Lotte New York Palace Hotel in New York, NY.

To access the live webcast presentation, please visit the Events & Presentations page within the Investors section of the G1 website. The webcast will be archived on the same page for 90 days following the event.

About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs. Trilaciclib is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy. Trilaciclib has received Breakthrough Therapy Designation from the FDA; a rolling NDA submission for small cell lung cancer will begin in 4Q19 and is expected to be completed in the second quarter of 2020. Lerociclib is a differentiated oral CDK4/6 inhibitor designed to enable more effective combination treatment strategies. G1T48 is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. G1 Therapeutics also has an active discovery program focused on cyclin-dependent kinase targets.

G1 is based in Research Triangle Park, NC. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contact:
Jeff Macdonald
Senior Director, Investor Relations & Corporate Communications
919-907-1944
jmacdonald@g1therapeutics.com